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Purpose/Objective: Electron Intra Operative Radiation Therapy has 
been extensively tested in Milan since 1999. After a pilot trial on 101 
patients in order to identify the maximum tolerated dose, a 
randomized study, named ELIOT,has been carried out from 2000 to 
2007. Aims of the study was to compare patients submitted to a 21 Gy 
single-fraction treatment targeted at the tumour bed only, given at 
the time of the quadrantectomy, versus standard post-operative WBI 
after the same BCS. 
Materials and Methods: We didn’t select specific subgroups of 
patients theoretically at higher or lower risk. Eligible patients were 
women with early invasive ductal or lobular breast cancer with a 
maximum diameter up to 25 mm if they were aged between 48 and 75 
years old and suitable for BCS. The study protocol was approved by 
the institutional ethical committee and a written informed consent 
was obtained from eligible patients before assignment to treatment. 
The primary endpoint was the incidence of local relapse, including 
ipsilateral breast cancer. Based on literature data available at the 
time of the study design (July 2000) and our previous experience, the 
expected 5-years rate in the conventional arm was about 3%. Tobe 
equivalent the observed rate should be kept under the 7.5% in the 
ELIOT arm. Secondary endpoints included overall survival, incidence 
of axillary or distant metastasis, contralateral breast cancer, and 
other primary cancers. 
Results: A total of 1305 breast cancer patients were randomized 
before surgery in the study (654 in the WBI arm and 651 in the ELIOT 
arm). Due to ineligibility, 119 patients were excluded and a total of 
1186 patients were available for analysis (601 in the WBI arm and 585 
in the ELIOT arm). The analysis is based on effective treatment 
received and not an intention-to-treat. The two treatment groups 
were perfectly comparable at baseline, with only tumor grade 
differentially distributed with a higher frequency of G1 tumor in the 
ELIOT arm (p=0.03). All the events are reported at the 5-year follow-
up. An excess of “true local relapses” (WBI = 5/ ELIOT = 23), 
“ipsilateral breast cancer”(0/14, respectively) and “axillary/regional 
lymphonode metastases” (2/9, respectively) in the ELIOT group were 
observed. An excess of controlateral breast cancer, but without 
significant statistical difference, was observed in the conventional 
arm, 1.7% versus 0.8%. If we consider the cumulative incidence of new 
cancers not related to the recurrence in index quadrant (ipsilateral 
and contralateral second cancer) we observed a rate of 1.7 in the WBI 
arm, and 2.9in the ELIOT arm.  We found a low rate of local relapse in 
women with small tumor (≤1cm), grade 1 tumor and luminal A tumor. 
Among 200 patients with small (≤1cm) luminal A breast cancer we 
observed only one local relapse in the WBI group versus 2 in the ELIOT 
group (log-rank p=0.55). Among 986 patients with either large (>1cm) 
or non luminal A breast cancer we observed 4 local relapses in the WBI 
group versus 35 in the ELIOT group (log-rank p<0.0001). In order to 
assess some subgroups of patients to be selected for ELIOT treatment 
without statistical differences with the conventional arm, we 
stratified the patients according to the ASTRO criteria. We had 129 
patients in the “suitable” group,270 in the “cautionary”, and 184 in 
the “unsuitable group. In the low risk group no statistical differences 
have been observed between the two arms. No differences were 
observed in death rate and overall survival. The actuarial10-year 
overall survival rates were 92.0 and 89.8, respectively (P=0.69). 
Conclusions: This study contributes to identify properly selected 
patients for PBI. New issues of biology-oriented patient selection need 
to be validated with independent data sets and new generation of 
randomized trials. 
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Purpose/Objective: To compare 1-year toxicities of accelerated 
partial breast irradiation (APBI) with multicatheter brachytherapy (BT) 
to whole breast irradiation (WBI) in a low-risk group of breast 
carcinoma. 
Materials and Methods: Between May 2004 and July 2009, 1195 
eligible patients with Stage 0/I/II (pTis-1-2 pN0-1mi M0) breast cancer 
were prospectively enrolled on the protocol. Patients allocated to the 
standard arm received 50 Gy WBI followed by a tumor bed boost of 10 
Gy. Patients in the experimental arm were treated with APBI using 
multicatheter BT up to 32.0 Gy/8 fractions or 30.3 Gy/7 fractions 
(HDR-BT) or up to 50 Gy/0.60-0.80 Gy (1 pulse/hour, 24 hours/day; 
PDR-BT). We report early side-effects and 1-year toxicities of 1193 
patients, who were treated according to study protocol (WBI: n=560 
vs. APBI: n=633). Side effects were documented according to the CTC-
AE v3 and the RTOG/EORTC late radiation morbidity scoring schemes. 
The cosmetic outcome was judged by digital photographs. This study 
is registered at ClinicalTrials.gov: NCT00402519.  
Results: Both WBI and APBI were well tolerated with moderate early 
side-effects at the end of therapy: acute dermatitis (Grade 1: 49.5% 
vs. 18.2%, Grade 2: 35.7% vs. 2.1%, Grade 3: 7.1% vs. 0.2%; p<0.0001), 
breast pain (Grade 1: 31.6% vs. 27.1%, Grade 2: 3.1% vs. 3.4%, p=0.2), 
hematoma (Grade 1: 1.8% vs. 18.8%, Grade 2: 0.8% vs. 0.6%; 
p<0.0001), breast infection (Grade 1: 2.0% vs. 4.5%, Grade 2: 0.2% vs. 
0.5%, Grade 3: 0.2% vs. 0.2%; p=0.09) in the WBI and APBI arm, 
respectively. At 1 year follow-up, significant differences were 
observed between WBI and APBI regarding skin atrophy (Grade 0: 
72.3% vs. 77.8%, Grade 1: 24.0% vs. 21.2%, Grade 2: 3.7% vs. 1.1%; 
p=0.0182) and hyperpigmentation of the skin (Grade 0: 72.7% vs. 
78.5%, Grade 1: 24.4% vs. 20.9%, Grade 2: 3.0% vs. 0.65%; p=0.0126), 
respectively. Regarding other late side-effects as fibrosis, fat 
necrosis, brachial lymphedema, breast pain, teleangiectasia, and 
cosmesis no significant difference was observed between the 
treatment arms at 1-year follow-up.  
Conclusions: Both WBI and APBI are well tolerated and side-effects 
are minimal. One-year late toxicity data suggest that APBI using 
multicatheter BT is associated with significantly less skin related side-
effects compared to WBI. 
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Purpose/Objective: TARGIT-A is an international prospectively 
randomized trial to compare conventional external-beam RT to 'single-
shot' IORT using Intrabeam (Carl Zeiss). The IORT is usually given at 
the same operative procedure and under the same anaesthesia as the 
definitive wide local surgical excision. If unexpected adverse 
pathological features were detected at subsequent pathological 
review, the protocol dictated that EBRT could be added to this group, 
enabling a 'risk-adapted' policy for those with a documented 
additional risk of recurrence, rather than recommending standard 
EBRT for every patient. 
Materials and Methods: Between 2000 and 2012, 3,451 pts with 
unifocal invasive breast carcinoma, aged 45 yrs or over and suitable 
for breast-conserving surgery, were enrolled from 33 centres in 10 
countries. Randomisation could be performed either before the 
surgery (pre-pathology group) or after surgery when the definitive 
pathological review was available (post-pathology group). IORT added 
approx 30-40 min to the procedure. Primary outcome: in-breast 
ipsilateral recurrence (IBR) for all pts, and also assessed separately for 
pre- and post-pathology groups. We specified a 2.5% 'non-inferiority' 
margin for IBR at 5 yrs. Secondary outcome: survival. Exploratory 
analyses: other recurrences incl distant; total death rate; causes of 
death, in particular from breast cancer or other causes. 
Results: The total no. of pts in study was 3451. Patient numbers were 
1721 (TARGIT) and 1730 (EBRT). 1010 pts have a minimum 4 yr follow-
up and 611 have been followed for 5 yrs. Median f/u for the whole 
group = 2.5 yrs. Because of adverse pathological factors, about 15% of 
pts in the IORT group also received EBRT - i.e about 85% did not. This 
